---
document_datetime: 2025-12-02 05:27:31
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/glustin.html
document_name: glustin.html
version: success
processing_time: 0.1138928
conversion_datetime: 2025-12-28 15:18:44.695291
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Glustin

[RSS](/en/individual-human-medicine.xml/65446)

##### Withdrawn

This medicine's authorisation has been withdrawn

pioglitazone Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Glustin](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 30 November 2021, the European Commission withdrew the marketing authorisation for Glustin (pioglitazone) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Takeda Pharma A/S, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Glustin was granted marketing authorisation in the EU on 11 October 2000 for the treatment of type 2 diabetes. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2005. It was then granted unlimited validity in 2010. The product had not been marketed in the EU since 2019. Glustin was a duplicate application to Actos, which is marketed in several EU countries.

The European Public Assessment Report (EPAR) for Glustin is updated to indicate that the marketing authorisation is no longer valid.

Glustin : EPAR - Summary for the public

English (EN) (678.57 KB - PDF)

**First published:** 16/09/2008

**Last updated:** 17/10/2022

[View](/en/documents/overview/glustin-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-637)

български (BG) (774.66 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/bg/documents/overview/glustin-epar-summary-public_bg.pdf)

español (ES) (676.99 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/es/documents/overview/glustin-epar-summary-public_es.pdf)

čeština (CS) (756.82 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/cs/documents/overview/glustin-epar-summary-public_cs.pdf)

dansk (DA) (676.89 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/da/documents/overview/glustin-epar-summary-public_da.pdf)

Deutsch (DE) (680.07 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/de/documents/overview/glustin-epar-summary-public_de.pdf)

eesti keel (ET) (674.06 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/et/documents/overview/glustin-epar-summary-public_et.pdf)

ελληνικά (EL) (115.77 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/el/documents/overview/glustin-epar-summary-public_el.pdf)

français (FR) (679.7 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/fr/documents/overview/glustin-epar-summary-public_fr.pdf)

hrvatski (HR) (696.95 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/hr/documents/overview/glustin-epar-summary-public_hr.pdf)

italiano (IT) (676.4 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/it/documents/overview/glustin-epar-summary-public_it.pdf)

latviešu valoda (LV) (752.68 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/lv/documents/overview/glustin-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (702.48 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/lt/documents/overview/glustin-epar-summary-public_lt.pdf)

magyar (HU) (747.46 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/hu/documents/overview/glustin-epar-summary-public_hu.pdf)

Malti (MT) (756.84 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/mt/documents/overview/glustin-epar-summary-public_mt.pdf)

Nederlands (NL) (677.05 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/nl/documents/overview/glustin-epar-summary-public_nl.pdf)

polski (PL) (114.23 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/pl/documents/overview/glustin-epar-summary-public_pl.pdf)

português (PT) (677.65 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/pt/documents/overview/glustin-epar-summary-public_pt.pdf)

română (RO) (108.66 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/ro/documents/overview/glustin-epar-summary-public_ro.pdf)

slovenčina (SK) (113.17 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/sk/documents/overview/glustin-epar-summary-public_sk.pdf)

slovenščina (SL) (106.75 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/sl/documents/overview/glustin-epar-summary-public_sl.pdf)

Suomi (FI) (86.19 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/fi/documents/overview/glustin-epar-summary-public_fi.pdf)

svenska (SV) (677.63 KB - PDF)

**First published:**

16/09/2008

**Last updated:**

17/10/2022

[View](/sv/documents/overview/glustin-epar-summary-public_sv.pdf)

Glustin : EPAR - Risk-management-plan summary

English (EN) (837.84 KB - PDF)

**First published:** 02/03/2021

**Last updated:** 17/10/2022

[View](/en/documents/rmp-summary/glustin-epar-risk-management-plan-summary_en.pdf)

## Product information

Glustin : EPAR - Product Information

English (EN) (1.02 MB - PDF)

**First published:** 05/10/2009

**Last updated:** 17/10/2022

[View](/en/documents/product-information/glustin-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-209)

български (BG) (1.94 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/bg/documents/product-information/glustin-epar-product-information_bg.pdf)

español (ES) (1.08 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/es/documents/product-information/glustin-epar-product-information_es.pdf)

čeština (CS) (1.66 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/cs/documents/product-information/glustin-epar-product-information_cs.pdf)

dansk (DA) (1.05 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/da/documents/product-information/glustin-epar-product-information_da.pdf)

Deutsch (DE) (1.01 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/de/documents/product-information/glustin-epar-product-information_de.pdf)

eesti keel (ET) (1.05 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/et/documents/product-information/glustin-epar-product-information_et.pdf)

ελληνικά (EL) (2.07 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/el/documents/product-information/glustin-epar-product-information_el.pdf)

français (FR) (1.09 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/fr/documents/product-information/glustin-epar-product-information_fr.pdf)

hrvatski (HR) (339.47 KB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/hr/documents/product-information/glustin-epar-product-information_hr.pdf)

íslenska (IS) (1.05 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/is/documents/product-information/glustin-epar-product-information_is.pdf)

italiano (IT) (1.08 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/it/documents/product-information/glustin-epar-product-information_it.pdf)

latviešu valoda (LV) (1.7 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/lv/documents/product-information/glustin-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.11 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/lt/documents/product-information/glustin-epar-product-information_lt.pdf)

magyar (HU) (1.72 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/hu/documents/product-information/glustin-epar-product-information_hu.pdf)

Malti (MT) (1.72 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/mt/documents/product-information/glustin-epar-product-information_mt.pdf)

Nederlands (NL) (1.04 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/nl/documents/product-information/glustin-epar-product-information_nl.pdf)

norsk (NO) (1.05 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/no/documents/product-information/glustin-epar-product-information_no.pdf)

polski (PL) (1.7 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/pl/documents/product-information/glustin-epar-product-information_pl.pdf)

português (PT) (1.07 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/pt/documents/product-information/glustin-epar-product-information_pt.pdf)

română (RO) (1.15 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/ro/documents/product-information/glustin-epar-product-information_ro.pdf)

slovenčina (SK) (1.68 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/sk/documents/product-information/glustin-epar-product-information_sk.pdf)

slovenščina (SL) (1.72 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/sl/documents/product-information/glustin-epar-product-information_sl.pdf)

Suomi (FI) (1.07 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/fi/documents/product-information/glustin-epar-product-information_fi.pdf)

svenska (SV) (1.08 MB - PDF)

**First published:**

05/10/2009

**Last updated:**

17/10/2022

[View](/sv/documents/product-information/glustin-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/1979/G 04/02/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Glustin : EPAR - All Authorised presentations

English (EN) (585.22 KB - PDF)

**First published:** 13/02/2008

**Last updated:** 17/10/2022

[View](/en/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-62)

български (BG) (674.52 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/bg/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_bg.pdf)

español (ES) (586.87 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/es/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_es.pdf)

čeština (CS) (631.6 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/cs/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (585.4 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/da/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (587.16 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/de/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (587.65 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/et/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (681.57 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/el/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_el.pdf)

français (FR) (587.75 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/fr/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (627.09 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/hr/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (612.85 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/is/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_is.pdf)

italiano (IT) (587.18 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/it/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (667.03 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/lv/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (616.34 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/lt/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (632.78 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/hu/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (662.22 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/mt/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (587.07 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/nl/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (603.15 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/no/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_no.pdf)

polski (PL) (634.4 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/pl/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_pl.pdf)

português (PT) (587.8 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/pt/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_pt.pdf)

română (RO) (647.54 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/ro/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (667.31 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/sk/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (602.94 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/sl/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (588.27 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/fi/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (588.09 KB - PDF)

**First published:**

13/02/2008

**Last updated:**

17/10/2022

[View](/sv/documents/all-authorised-presentations/glustin-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Glustin Active substance pioglitazone hydrochloride International non-proprietary name (INN) or common name pioglitazone Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BG03

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:

- as **monotherapy:**
    - in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance.
- as **dual oral therapy** in combination with:
    - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;
    - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;
- as **triple oral therapy** in combination with:
    - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.

Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.

After initiation of therapy with pioglitazone, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

## Authorisation details

EMA product number EMEA/H/C/000286 Marketing authorisation holder

Takeda Pharma A/S

Delta Park 45

Marketing authorisation issued 11/10/2000 Revision 28

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Glustin : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.01 MB - PDF)

**First published:** 05/10/2009

**Last updated:** 17/10/2022

[View](/en/documents/procedural-steps-after/glustin-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Glustin-H-C-PSUSA-00002417-201807 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/241767/2019

English (EN) (648.01 KB - PDF)

**First published:** 13/08/2019

**Last updated:** 17/10/2022

[View](/en/documents/scientific-conclusion/glustin-h-c-psusa-00002417-201807-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Glustin-H-C-286-PSUV-0056 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/566874/2013

English (EN) (678.9 KB - PDF)

**First published:** 18/12/2013

**Last updated:** 17/10/2022

[View](/en/documents/scientific-conclusion/glustin-h-c-286-psuv-0056-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Glustin-H-C-286-A20-0044 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/CHMP/940059/2011

English (EN) (955.03 KB - PDF)

**First published:** 07/05/2012

**Last updated:** 17/10/2022

[View](/en/documents/variation-report/glustin-h-c-286-a20-0044-epar-assessment-report-article-20_en.pdf)

Glustin-H-C-286-II-25 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (731.31 KB - PDF)

**First published:** 13/02/2008

**Last updated:** 17/10/2022

[View](/en/documents/scientific-discussion-variation/glustin-h-c-286-ii-25-epar-scientific-discussion-variation_en.pdf)

Glustin-H-C-286-II-26 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (894.49 KB - PDF)

**First published:** 13/02/2008

**Last updated:** 17/10/2022

[View](/en/documents/scientific-discussion-variation/glustin-h-c-286-ii-26-epar-scientific-discussion-variation_en.pdf)

Glustin : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (659.22 KB - PDF)

**First published:** 06/09/2006

**Last updated:** 17/10/2022

[View](/en/documents/steps-after-cutoff/glustin-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Glustin : EPAR - Scientific Discussion

English (EN) (1.02 MB - PDF)

**First published:** 06/09/2006

**Last updated:** 17/10/2022

[View](/en/documents/scientific-discussion/glustin-epar-scientific-discussion_en.pdf)

Glustin : EPAR - Procedural steps taken before authorisation

English (EN) (664.12 KB - PDF)

**First published:** 06/09/2006

**Last updated:** 17/10/2022

[View](/en/documents/procedural-steps/glustin-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Glustin

[European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer](/en/news/european-medicines-agency-clarifies-opinion-pioglitazone-risk-bladder-cancer) 21/10/2011

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer](/en/news/european-medicines-agency-recommends-new-contra-indications-warnings-pioglitazone-reduce-small-increased-risk-bladder-cancer) 21/07/2011

[European Medicines Agency updates on ongoing benefit-risk review of pioglitazone-containing medicines](/en/news/european-medicines-agency-updates-ongoing-benefit-risk-review-pioglitazone-containing-medicines) 23/06/2011

[Update on ongoing European review of pioglitazone-containing medicines](/en/news/update-ongoing-european-review-pioglitazone-containing-medicines) 09/06/2011

**This page was last updated on** 17/10/2022

## Share this page

[Back to top](#main-content)